BJDX

Bluejay Diagnostics Inc. (BJDX) | Rumor.io

Bluejay Diagnostics

BJDX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,233

Bullish sentiment (50-day avg)90%

Price to earnings ratio0

Market capitalization993.3K

Earnings per share-2.27

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-6.8M

Social

What share of all stock conversation is about BJDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 22

$BJDX is seen as a potential 5-10x play with a 45% move so far.
The company's book value is $4.75 per share with $9 million in cash, a current ratio of 4.64, and a debt-to-equity ratio of 0.86%.
$BJDX is considered oversold and has a potential merger offer with free $1.50 warrants.

Generated by AI

Sentiment

Of the messages about BJDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +3.1	90.67% +7.43	82.97% -6.47
Bearish	—	0% -3.1	9.33% -7.43	17.03% +6.47

Bullish· Sep 8

The warrants exercise price is $2, indicating that the whales will have to push the price up to meet this requirement, which could lead to a significant increase in the asset's value.
The asset has the potential to break through the resistance level of $1.11 and open at a price above $1.20, which could lead to a significant increase in its value.
The asset's price has the potential to reach $1.2-$1.4 today, with the news being a major factor in its expected price increase.

Bearish· Aug 5

The short interest relative to the floating shares is over 100%, indicating potential naked shorting and a possible "GameStop 2" scenario.
The company's dilution is rampant, with a 30M volume on a "1 M float" and no significant price movement, despite the high trading volume.
The stock's momentum is broken, and it may make a new low, with one post warning that it could be "rocket fuel" if it doesn't make a new low.

Generated by AI

Topics

Of the messages about BJDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	62.5%	26.49%
Technical Analysis	0%	0%	37.5%	33.37%
Analysts	0%	0%	0%	21.02%
Macro	0%	0%	0%	19.12%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%

Announcements· Jun 2

Bluejay Diagnostics, Inc. (BJDX) has announced a strategic partnership with Argonaut Manufacturing Services to establish U.S.-based production for its Symphony diagnostic platform.
The partnership aims to support the advancement of Bluejay's Symphony platform, which is a near-patient testing platform for critical care settings, and targets IL-6 testing for sepsis triage, monitoring, and diagnosis.
Bluejay Diagnostics has also raised up to $23.6 million in a private placement to fund FDA approval of its Symphony sepsis test, with an $8.5 million upfront payment and up to $15.1 million more if Series G and H warrants are fully exercised.

Technical Analysis· Aug 5

Watching for candle to close above vwap at $1.47 to trigger a potential breakout.
Resistance levels to retrace are $1.55, $1.61, $1.90, and $1.99; however, the tape does not look good, and it may be a coordinated pump.
The stock has a low float and is watching for strength above $1.55 with targets around $1.70/$1.80+.

Generated by AI

Community

Of the messages about BJDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	74.19%	37.1%	42%
Newcomers	0%	25.81%	62.9%	58%

Regulars· Sep 8

The partnership between Bluejay Diagnostics and Lovell Government Services has the potential to expand access to U.S. federal healthcare markets, pending clearance.
The stock has reached a high of $1.70 last month without news, and some participants are questioning whether it can surpass $1 with the recent good news of the partnership.
The stock's price has been increasing, with some participants noting a 20.5% pre-market gain, and others are watching for a break above $1.18 for potential further gains.

Newcomers· Sep 8

Newcomers are excited about the warrants exercise price of $2, expecting the whales to drive the price up.
Many posts discuss the potential for a 7am gapper, with some predicting prices in the range of $1.2-$1.4.
There is speculation about the company's government healthcare business, with some users calling it a key factor in the stock's potential.

Generated by AI

The Lovell Government Services agreement establishes federal procurement infrastructure for the Symphony platform, but commercialization remains dependent on regulatory authorization. Key Investor TakeawaysBluejay Diagnostics (NASDAQ:BJDX) has formed a distribution, co-marketing and strategic partnership with Lovell Government Services targeting U.

21d agoYahoo Finance

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

22d agoBenzinga

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare ChannelsACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and Lovell Government Services, Inc. (“Lovell”), a Service-Disabled Veteran-Owned Co

22d agoYahoo! Finance Canada

Bluejay Diagnostics completes enrollment in sepsis test study

1mo agoInvesting.com

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

SYMON-II pivotal clinical study completes targeted enrollment of 750 patientsCompany advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain riskCompany ends second quarter with approximately $9.6 million in cash following significant financing ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcom

1mo agoYahoo Finance

12 Health Care Stocks Moving In Wednesday's Intraday Session - Zhengye Biotechnology (NASDAQ:ZYBT), Bluej

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX) shares

1mo agoBenzinga

Also Discussed

Investors talking about BJDX also mention

#	Name	Attention
1	Decent Holding Inc. Class A Ordinary SharesDXST	0.02%new
2	Lucas GC Limited Ordinary SharesLGCL	0%0
3	SciSparc Ltd.SPRC	0%+0
4	SMART Trend 25 ETFSTRN	0%0
5	Biofrontera Inc.BFRI	0%0
6	BeneficientBENF	0.01%0
7	TNL Mediagene Ordinary SharesTNMG	0%new
8	Context Therapeutics Inc.CNTX	0%0
9	PTPI - Petros Pharmaceuticals, Inc.	——
10	Longeveron Inc. Class A Common StockLGVN	0%0

Bluejay Diagnostics Inc.

Healthcare
Medical Devices

Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings. Its core Symphony platform combines an analyzer and single-use cartridges to process whole blood and detect key biomarkers, supporting timely assessment of inflammation, infection, and cardiac conditions. The company’s current product development includes the Symphony IL-6 test for monitoring disease progression in critical care, along with additional assays targeting myocardial infarction and congestive heart failure. Bluejay Diagnostics also develops point-of-care diagnostic products designed to give healthcare providers faster, practical insights at the bedside. Headquartered in Acton, Massachusetts, Bluejay Diagnostics Inc. serves the healthcare market through technologies aimed at improving diagnostic workflows and supporting informed clinical decision-making.

Website

Location

360 Massachusetts Avenue

Acton, MA, 01720

United States

Social

What share of all stock conversation is about BJDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 22

$BJDX is seen as a potential 5-10x play with a 45% move so far.
The company's book value is $4.75 per share with $9 million in cash, a current ratio of 4.64, and a debt-to-equity ratio of 0.86%.
$BJDX is considered oversold and has a potential merger offer with free $1.50 warrants.

Generated by AI

Sentiment

Of the messages about BJDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +3.1	90.67% +7.43	82.97% -6.47
Bearish	—	0% -3.1	9.33% -7.43	17.03% +6.47

Bullish· Sep 8

The warrants exercise price is $2, indicating that the whales will have to push the price up to meet this requirement, which could lead to a significant increase in the asset's value.
The asset has the potential to break through the resistance level of $1.11 and open at a price above $1.20, which could lead to a significant increase in its value.
The asset's price has the potential to reach $1.2-$1.4 today, with the news being a major factor in its expected price increase.

Bearish· Aug 5

The short interest relative to the floating shares is over 100%, indicating potential naked shorting and a possible "GameStop 2" scenario.
The company's dilution is rampant, with a 30M volume on a "1 M float" and no significant price movement, despite the high trading volume.
The stock's momentum is broken, and it may make a new low, with one post warning that it could be "rocket fuel" if it doesn't make a new low.

Generated by AI

Topics

Of the messages about BJDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	62.5%	26.49%
Technical Analysis	0%	0%	37.5%	33.37%
Analysts	0%	0%	0%	21.02%
Macro	0%	0%	0%	19.12%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%

Announcements· Jun 2

Bluejay Diagnostics, Inc. (BJDX) has announced a strategic partnership with Argonaut Manufacturing Services to establish U.S.-based production for its Symphony diagnostic platform.
The partnership aims to support the advancement of Bluejay's Symphony platform, which is a near-patient testing platform for critical care settings, and targets IL-6 testing for sepsis triage, monitoring, and diagnosis.
Bluejay Diagnostics has also raised up to $23.6 million in a private placement to fund FDA approval of its Symphony sepsis test, with an $8.5 million upfront payment and up to $15.1 million more if Series G and H warrants are fully exercised.

Technical Analysis· Aug 5

Watching for candle to close above vwap at $1.47 to trigger a potential breakout.
Resistance levels to retrace are $1.55, $1.61, $1.90, and $1.99; however, the tape does not look good, and it may be a coordinated pump.
The stock has a low float and is watching for strength above $1.55 with targets around $1.70/$1.80+.

Generated by AI

Community

Of the messages about BJDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	74.19%	37.1%	42%
Newcomers	0%	25.81%	62.9%	58%

Regulars· Sep 8

The partnership between Bluejay Diagnostics and Lovell Government Services has the potential to expand access to U.S. federal healthcare markets, pending clearance.
The stock has reached a high of $1.70 last month without news, and some participants are questioning whether it can surpass $1 with the recent good news of the partnership.
The stock's price has been increasing, with some participants noting a 20.5% pre-market gain, and others are watching for a break above $1.18 for potential further gains.

Newcomers· Sep 8

Newcomers are excited about the warrants exercise price of $2, expecting the whales to drive the price up.
Many posts discuss the potential for a 7am gapper, with some predicting prices in the range of $1.2-$1.4.
There is speculation about the company's government healthcare business, with some users calling it a key factor in the stock's potential.

Generated by AI

Bluejay Diagnostics

Social

Sep 22

Bullish· Sep 8

Bearish· Aug 5

Announcements· Jun 2

Technical Analysis· Aug 5

Regulars· Sep 8

Newcomers· Sep 8

Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Bluejay Diagnostics completes enrollment in sepsis test study

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

12 Health Care Stocks Moving In Wednesday's Intraday Session - Zhengye Biotechnology (NASDAQ:ZYBT), Bluej

Also Discussed

Bluejay Diagnostics Inc.

Company Information

Location

Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets

Bluejay Diagnostics completes enrollment in sepsis test study

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

12 Health Care Stocks Moving In Wednesday's Intraday Session - Zhengye Biotechnology (NASDAQ:ZYBT), Bluej

Also Discussed

Social

Sep 22

Bullish· Sep 8

Bearish· Aug 5

Announcements· Jun 2

Technical Analysis· Aug 5

Regulars· Sep 8

Newcomers· Sep 8